Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glycopyrrolate Clear all
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Minimizing Nausea and Vomiting During Spinals for CS

NCT02872935
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Glycopyrrolate, Normal Saline
Drug
Lead sponsor
Kokila N Thenuwara
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Time to Extubation Using Sugammadex or Neostigmine

NCT04606901
View directory record Official record
Conditions
Neuromuscular Blockade, Chronic Obstructive Pulmonary Disease
Interventions
neostigmine/glycopyrrolate, sugammadex
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT003, PT001, PT005, Tiotropium inhalation powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
19
States / cities
Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage

NCT00745095
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Neostigmine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761
View directory record Official record
Conditions
COPD
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo BID eFlow Closed System (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
44
States / cities
Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Neostigmine, Glycopyrrolate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

NCT03116997
View directory record Official record
Conditions
Surgery
Interventions
Neostigmine+glycopyrrolate, Sugammadex
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

NCT07016412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo eFlow (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
45
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

NCT00491894
View directory record Official record
Conditions
Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Interventions
Oral Glycopyrrolate Liquid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Years to 18 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

NCT07132983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 4 Interventional

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI

NCT00855283
View directory record Official record
Conditions
SCI
Interventions
IN NEO, IN NEO + IN Glycopyrrolate, IV Visit
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Sugammadex in Outpatient Urological Procedures

NCT03138967
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Interventions
Rocuronium, Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

NCT05887375
View directory record Official record
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Interventions
Sugammadex, Neostigmine, Glycopyrrolate, Rocuronium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated Phase 1 Interventional

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)

NCT01588717
View directory record Official record
Conditions
Hyperhydrosis, Depression
Interventions
Glycopyrrolate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol/glycopyrrolate, indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Neostigmine and Glycopyrrolate

NCT04027972
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Active, not recruiting Phase 3 Interventional

Neostigmine and Glycopyrrolate by Iontophoresis

NCT06351995
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02276222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
83
States / cities
Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jun 10, 2026, 1:27 PM EDT